Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 101.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,759 shares of the pharmaceutical company’s stock after acquiring an additional 40,766 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Vertex Pharmaceuticals were worth $32,373,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Dunhill Financial LLC increased its stake in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $33,000. Brown Lisle Cummings Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $30,000. Sugar Maple Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $35,000. Finally, Golden State Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $37,000. Institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on VRTX shares. Royal Bank of Canada upped their price target on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 20th. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. BMO Capital Markets set a $545.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Stifel Nicolaus upped their price objective on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Finally, Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $506.70.

Insider Activity

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the transaction, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ourania Tatsis sold 530 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the transaction, the executive vice president now owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. The trade was a 0.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $492.69 on Monday. The firm has a market capitalization of $126.52 billion, a price-to-earnings ratio of -223.95, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock has a fifty day moving average of $476.45 and a 200 day moving average of $463.64. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.